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A 70-year-old woman underwent extirpation of a malignantperipheral nerve sheath tumor, 4.5  2.0 cm in size, in
the right supraclavicular fossa. Locoregional recurrence was
found 10 months after operation (Figure 1). Although one
course of systemic chemotherapy using cisplatin (80 mg/m2
at day 1) and vinorelbine (25 mg/m2 at days 1 and 8) was
given, the recurrent tumor progressed. Because conventional
radiotherapy is not effective for malignant peripheral nerve
sheath tumor, boron neutron capture therapy (BNCT) was
considered based on the subcutaneous mediastinal location.
After institutional review board approval and securing the
patient’s written informed consent, accumulation of p-bo-
ronophenylalanine (BPA) in the tumor was confirmed using
18F-BPA positron emission tomography. Using simulation
environment for radiation applications software program, fast
neutron and -ray physical doses, compound biologic effec-
tiveness- and relative biologic effectiveness-weighted doses,
were calculated.
The patient underwent two courses of BNCT with an
interval of 3 weeks. BPA-fructose was administered intrave-
nously at a dose of 500 mg/kg just before irradiation. For the
first course, the epithermal neutron irradiation was performed
for 105 minutes. The dose distribution in the tumor ranged
from 13.7 to 22.3 Gy-Eq and was 6.0 Gy-Eq to the skin. For
the second course, the irradiation time was shortened to 51
minutes, because of the higher epithermal neutron flux. The
dose delivered to the tumor ranged from 6.0 to 24.3 Gy-Eq
and was 9.7 Gy-Eq to the skin.
Chest computed tomography scan 1 year after BNCT
showed that the tumor size decreased from 6.2  4.0 cm to
4.6  3.2 cm in size (25% reduction), and stable disease was
maintained for 24 months (Figure 2). Positron emission tomog-
raphy-computed tomography 18 months after BNCT showed no
uptake of 18F-fluorodeoxy glucose in the residual mass, sug-
gesting no viability (Figure 3). Neuralgia of the right arm
improved. Although temporary dysphagia because of an oral
mucosa disorder was observed as a side effect, the patient’s
general quality of life was preserved. There is no evidence of
recurrence 2 years after BNCT.
DISCUSSION
When 10Boron absorbs thermal neutrons,  and 7Lith-
ium particles are generated.1 BNCT selectively injures the
tumor cells containing 10Boron; it was suitable in this case
with tumor invasion into the neighboring great vessels. Be-
cause the peak of thermal neutron flux is 3 cm beneath the
tissue surface, its clinical applications have been limited to
malignant melanomas and brain tumors. Kato et al.2 reported
its efficacy for head and neck malignancies. The indication
was extended to metastatic liver tumor,3 malignant mesothe-
lioma,4 and glioblastoma.5 This is the first case of mediastinal
tumor treated with BNCT.
The effect of BNCT is critically dependent on selective
accumulation of 10Boron compounds. The tumor/normal tis-
sue ratio of the 10Boron uptake was 2 in this case, while a
ratio greater than 2.5 is preferable for selective treatment.
BNCT might be a treatment option for subcutaneous medi-
astinal tumors, which is resistant to conventional irradiation.
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FIGURE 3. FDG-positron emission
tomography (PET) shows the re-
markable effect of boron neutron
capture therapy (BNCT). A, PET-
computed tomography (CT) before
BNCT shows significant tumor up-
take. B, Although a residual mass is
seen, the FDG uptake is reduced to
the background level 18 months
after BNCT.
FIGURE 1. Chest computed to-
mography (CT) scan and magnetic
resonance imaging (MRI) showing
the recurrent lesion. A, Postopera-
tive recurrence, 4.5  2.0 cm in
size, is seen in the right subclavicu-
lar region (arrow head) in the fol-
low-up CT scan 10 months after
operation. B, Tumor invasion into
the right subclavicular artery and
brachiocephalic vein is seen (arrow
head) in the sagittal view of MRI.
FIGURE 2. Chest computed tomography scan 1 year after
boron neutron capture therapy shows shrinkage of the re-
current lesion after chemotherapy from 6.2  4.0 cm to
4.6  3.2 cm in size (25% reduction).
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